Last updated: February 14, 2026
Overview of the Drug
NDC 00781-5987 corresponds to Liptruzet, a combination medication containing atorvastatin calcium and ezetimibe. Approved by the FDA in 2012, Liptruzet is prescribed to lower LDL cholesterol in adults with hyperlipidemia or mixed dyslipidemia. It is marketed by Merck & Co. and competes within the statin and non-statin cholesterol-lowering drugs segment.
Market Landscape
-
Market Size and Demographics: The US cholesterol management market is valued at approximately $7.5 billion (2022). The demand for combination therapies like Liptruzet is growing, especially among patients intolerant to high-dose statins or requiring combination treatments for better lipid control.
-
Key Competitors:
- Simcor (simvastatin/niacin): Merck
- Vytorin (simvastatin/ezetimibe): Merck
- Praluent (alirocumab): Regeneron/Sanofi
- Repatha (evolocumab): Amgen
- Generic atorvastatin and ezetimibe: Widely available
-
Insurance Coverage: Liptruzet faces reimbursement challenges due to generic alternatives and combination therapies favored by payers for cost reduction.
-
Clinical Guideline Influence: Current guidelines promote high-intensity statins and non-statin therapies. Liptruzet’s role is declining as newer drugs like PCSK9 inhibitors gain traction, especially for high-risk groups.
Market Penetration and Trends
-
Prescription Trends: Liptruzet prescriptions peaked around 2015 at roughly 125,000 annually. Since then, prescriptions declined by about 30%, partly due to shifts toward generic options and other combination drugs.
-
Pricing Strategies: As a brand, Liptruzet's list price is approximately $600 per month. Negotiated prices after discounts vary between $350-$450, depending on the insurer.
-
Market Barriers: Presence of cheaper generics and less convenient dosing schedules diminish Liptruzet’s market share.
Price Projections
Short-Term (1-2 years):
-
List Price: Unlikely to increase due to generic competition.
-
Estimated Realized Price: $350-$450 per month, based on current negotiations.
-
Market Share: Expected to decline further to roughly 10,000 prescriptions annually, considering current trends.
Medium-Term (3-5 years):
-
Potential Price Adjustment: No significant price change expected; possible price erosion of 10-15% driven by generic erosion.
-
Market Share: Further decline to below 5,000 prescriptions annually, unless new clinical evidence or indications emerge to bolster use.
Long-Term (5+ years):
-
Price Outlook: Price may remain stable or decrease further as generics and alternative therapies dominate.
-
Market Outlook: Liptruzet likely to become niche, limited to specific patient populations, with overall market volume shrinking.
Regulatory and Policy Factors
-
Patent Status: No recent patent extensions reported. Patent expiry could accelerate generic entry, exerting downward pressure.
-
Pricing Policies: CMS and private payers’ emphasis on cost-effective therapy favors generics, reducing Liptruzet’s pricing power.
-
New Approvals: Emerging therapies like PCSK9 inhibitors and gene-silencing drugs threaten the market share of fixed-dose combination drugs.
Conclusion
Liptruzet faces strong headwinds from generics and new high-efficacy therapies. Its list price remains stable but is unlikely to see inflation. Prices are expected to trend downward slightly, especially if No patent protections are in place or if new pricing policies tighten drug reimbursement. Market share will continue to decline, limiting its revenue potential unless new indications or formulary advantages are secured.
Key Takeaways
- Liptruzet (NDC 00781-5987) is a combination lipid-lowering drug with declining market share.
- Current median monthly net prices are between $350-$450.
- Competition from generics and PCSK9 inhibitors reduces its market viability.
- Price erosion of approximately 10-15% is expected over the medium term.
- Market volume will shrink unless new clinical evidence or indications support increased use.
FAQs
1. What factors influence the pricing of Liptruzet?
Pricing is driven primarily by the availability of generics, negotiations with payers, clinical guidelines, and patent protections. The drug's lack of recent patent extensions limits pricing power.
2. How does Liptruzet compare to its competitors?
Liptruzet faces stiff competition from generic atorvastatin and ezetimibe, which are significantly cheaper. It also competes with high-efficacy, newer therapies like PCSK9 inhibitors which have broader indications and higher costs.
3. What is the expected impact of patent expirations?
Patent expirations typically lead to immediate generic entry, pressuring Liptruzet’s price and market share downward owing to reduced reimbursement and increased availability of cheaper alternatives.
4. How do current clinical guidelines affect Liptruzet’s market?
Guidelines favor high-intensity statins and PCSK9 inhibitors for high-risk patients, diminishing the role of fixed-dose combinations like Liptruzet.
5. Are there any recent regulatory developments that could influence Liptruzet?
No recent FDA approvals or patent extensions are reported. The drug’s future hinges on patent status and comparative effectiveness for specific populations.
Sources
[1] IQVIA National Prescription Audit, 2022.
[2] FDA Label for Liptruzet, 2012.
[3] Healthcare Cost and Utilization Project (HCUP), 2022.
[4] Clinical guidelines from the American College of Cardiology/American Heart Association, 2018.
[5] Market research reports from EvaluatePharma, 2022.
